Thank you for subscribing!
Finfeed Archived Jun 03, 2021
In what is a major development for Creso Pharma (ASX: CPH), target acquisition company Halucencex Life Sciences is fast tracking its go to market strategy in California. This follows the recent passing of Senate Bill 519 through the California State Senate, which if signed into law, would make a wide range of psychedelic substances including psilocybin legal to use and possess for adults over the age of 21.
Finfeed Archived May 14, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) target acquisition company Halucenex Life Sciences has nearly doubled its supply of synthetic psilocybin. Halucenex has secured an additional 10 grams of synthetic psilocybin from its manufacturing partner – Canada’s only pharmaceutical grade synthetic psilocybin producer.
Finfeed Archived May 06, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) has today announced that its acquisition target Halucenex Life Sciences Inc. has signed an agreement with Nucro-Technics, a Pharmaceutical Contract Research Organization (CRO) that is a partner to pharmaceutical, biologic, and medical device companies located all over the world.
Finfeed Archived Apr 30, 2021
There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.
Get expert stock analysis direct in your inbox
Finfeed Archived Apr 19, 2021
Creso Pharma Limited’s (ASX:CPH, FRA:1X8) target acquisition company Halucencex Life Sciences Inc. has signed a non-binding Letter of Intent (LOI) with leading nanotechnology company Sixth Wave Inc. as California pushes to decriminalise psychedelics, which highlights the ongoing acceptance and regulatory shift towards psychedelics as an alternative treatment route for debilitating mental health conditions.
Finfeed Archived Mar 31, 2021
Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.
Next Investors Mar 26, 2021
Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.
Finfeed Archived Mar 23, 2021
Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.
Finfeed Archived Mar 18, 2021
Australia’s federal government will grant $15M to clinical studies that explore the use of psychedelic drugs like magic mushrooms and ecstasy, to treat Australians with debilitating mental illnesses.
Finfeed Archived Mar 15, 2021
Creso Pharma Limited (ASX:CPH, FRA:1X8) has signed an agreement to acquire Halucenex Life Sciences Inc. (Halucenex), an established psychedelics company focused on developing treatments for Treatment Resistant Depression in individuals suffering from PTSD, and other mental health illnesses.
Next Investors Mar 15, 2021
Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.
Join Our Mailing List
